Biopharmx (BPMX) Set to Announce Quarterly Earnings on Wednesday

Biopharmx (NYSEAMERICAN:BPMX) is scheduled to be announcing its earnings results on Wednesday, March 21st. Analysts expect the company to announce earnings of ($0.04) per share for the quarter.

Shares of Biopharmx (NYSEAMERICAN BPMX) opened at $0.31 on Wednesday. The stock has a market capitalization of $45.42, a price-to-earnings ratio of -1.15 and a beta of 0.43. Biopharmx has a 52 week low of $0.10 and a 52 week high of $0.90.

In other Biopharmx news, major shareholder Vivo Capital Viii, Llc sold 2,000,000 shares of the firm’s stock in a transaction on Wednesday, March 7th. The stock was sold at an average price of $0.36, for a total value of $720,000.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Separately, Maxim Group restated a “buy” rating and issued a $1.50 price target on shares of Biopharmx in a research note on Friday, December 8th.

COPYRIGHT VIOLATION WARNING: “Biopharmx (BPMX) Set to Announce Quarterly Earnings on Wednesday” was originally posted by Week Herald and is owned by of Week Herald. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The legal version of this news story can be viewed at

About Biopharmx

BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.

Earnings History for Biopharmx (NYSEAMERICAN:BPMX)

Receive News & Ratings for Biopharmx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx and related companies with's FREE daily email newsletter.

Leave a Reply